Nasal stem cells help unlock HSP secrets

Posted - February 2013 in Research Highlights

Promising progress towards a cure

 

Dr. Greger Abrahamsen

Dr. Greger Abrahamsen

In one of a kind research studying SPG 4 HSP stem cells derived from nasal tissue, researchers from the National Centre for Adult Stem Cell Research in Queensland have discovered new and important information on the impairments caused by the SPG 4 mutation, and on potential ways to reverse or compensate for the causes of these impairments.

 

The HSP Research Foundation has given significant financial support to fund this groundbreaking research.

 

Hereditary spastic paraplegia (HSP) leads to progressive gait disturbances with lower limb muscle weakness and spasticity. Mutations in SPAST are a major cause of adult-onset, autosomal-dominant HSP. Spastin, the protein encoded by SPAST, is a microtubule-severing protein that is enriched in the distal axon of corticospinal motor neurons, which degenerate in HSP patients. Animal and cell models have identified functions of spastin and mutated spastin but these models lack the gene dosage, mutation variability and genetic background that characterize patients with the disease.

 

In this study, this genetic variability is encompassed by comparing neural progenitor cells derived from biopsies of the olfactory mucosa from healthy controls with similar cells from HSP patients with SPAST mutations, in order to identify cell functions altered in HSP. Patient-derived cells were similar to control-derived cells in proliferation and multiple metabolic functions but had major dysregulation of gene expression, with 57% of all mRNA transcripts affected, including many associated with microtubule dynamics.

 

Compared to control cells, patient-derived cells had 50% spastin, 50% acetylated α-tubulin and 150% stathmin, a microtubule-destabilising enzyme. Patient-derived cells were smaller than control cells. They had altered intracellular distributions of peroxisomes and mitochondria and they had slower moving peroxisomes.

 

These results suggest that patient-derived cells might compensate for reduced spastin, but their increased stathmin expression reduced stabilised microtubules and altered organelle trafficking.

 

Sub-nanomolar concentrations of the microtubule-binding drugs, paclitaxel and vinblastine, increased acetylated α-tubulin levels in patient cells to control levels, indicating the utility of this cell model for screening candidate compounds for drug therapies.

 

SOURCE:  Dis Model Mech. 2013 Jan 18. [Epub ahead of print]  PMID: 23264559 [PubMed – as supplied by publisher]

A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations.

Abrahamsen G, Fan Y, Matigian N, Wali G, Bellette B, Sutharsan R, Raju J, Wood SA, Veivers D, Sue CM, Mackay-Sim A.

 

Griffith University, Brisbane, Australia

 

Add your comment on this story